Institute for Cancer Research
Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.
The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.
Scientific production - Institute for Cancer Research
David Russell from the Department of Neurology at the Division of Surgery and Clinical Neuroscience at Oslo University Hospital welcomes participants to the 5th national conference on stroke - "den 5 Nasjonale konferanse om Hjerneslag".
Every year 16.000 Norwegians are stricken with stroke, and more than 60.000 have previously had one or more strokes. It is therefore important that the foremost Norwegian experts in the field gather in order and be updated on what is new within preventive, acute treatment and rehabilitation from stroke.
Final date for registration is February 1st 2015.
The Neurogenetic laboratory is now pleased to offer the research community its competence in genotyping. The service is optimal for genotyping of low to moderate number of genetic variants.
Aina Rengmark (photo) is postdoc and responsible for the service facility. “Using optimized assays we can offer very competitive prices”, she says. Normally the total price including labor will be lower than the assay costs for the commonly used TaqMan technology.
The 2014 "Dr. Ragnar Mørk's legacy prize" went to Arne Kolstad from the Department of Oncology for his excellent clinical research on lymphoma therapy.
This annual award of NOK 200.000 is given to scientists affiliated to the Norwegian Radium Hospital who have obtained important results within the field of cancer research.
The ceremony took place Friday November 21st in the Research Building at Montebello. Kolstad gave an interesting lecture about the research activities that has earned him the award.
Oslo University Hospital has rewarded six research groups for their excellent papers published during the first half-year of 2014. Each group receives NOK 50.000 for use in further research. The prizes were distributed during the Friday meeting at Ullevål November 21st.
The award winners gave short presentations of the main findings in their respective articles. Managing director Bjørn Erikstein (photo) distributed the awards, and professor Ole M. Sejerstad chaired the meeting.
The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.
Mouldy Sioud from Department of Immunology at the Institute for Cancer Research is the editor of a new book published November 10th entitled "RNA Interference: Challenges and Therapeutic Opportunities". The book is included in the series "Methods in Molecular Biology, Vol. 1218" and provides readers with recent advances in siRNA design, delivery, targeting and methods to minimize siRNA's unwanted effects. Preclinical and clinical use of synthetic siRNAs, the roles of miRNAs in cancer and the promise of extracellular miRNAs for diagnosis are also covered in this meticulous collection, along with novel methods for identifying endogenous siRNAs and the annotation of small RNA transcriptomes.
The recently launched Oslo University Hospital research blog is the first of this kind among Norwegian health care institutions. The blog acts as a platform for communicating discoveries in medical sciences in a popularised form, as well as serving as a vehicle for the hospital to stay in touch with the community. It will also be used as a channel for voicing the views of the hospital in debates concerning research policies. The blog is in Norwegian. New contributions will appear on the blog every other week, starting with the heads of research at the various divisions writing in turn. The current contribution is by Karin C. Lødrup Carlsen, head of research at the Women and Children's Division.
Nov 18, 2014
Inst. for Cancer Research
Journal Impact Factor > 5, first or last author from the Institute for Cancer Research
The multitude of molecular analyses in cancer: the opening of Pandora's box
Genome Biol, 15 (9), 447 (in press)
DNA Methylation Status of Key Cell-Cycle Regulators Such as CDKNA2/p16 and CCNA1 Correlates with Treatment Response to Doxorubicin and 5-Fluorouracil in Locally Advanced Breast Tumors
Clin Cancer Res (in press)